Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$17.02 - $50.98
Next Earnings Date
May 06 2025
Next Earnings Date
May 06 2025
Latest price
Market Cap | $2.20B |
EV | $2.25B |
Shares Outstanding | 125.52M |
Beta | 0.84 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | $42.20 |
P/E 2025E | - |
P/Revenue 2025E | 2.55x |
Revenue | 127.30% |
EPS | 43.40% |
Operating Cash Flow | 46.20% |
Free Cash Flow | 46.10% |
Revenue | 18.20% |
EPS | - |
Operating Cash Flow | - |
Free Cash Flow | - |
Gross Margin 2025E | 85.36% |
Net Profit Margin 2025E | -15.10% |
ROE 2025E | -61.43% |
ROCE 2024 | -93.55% |
DPS 2025E | $0.00 |
Payout Ratio 2025E | 0.00% |
Div. Yield 2025E | 0.00% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Apellis Pharmaceuticals, Inc.
APLS
Sector
Healthcare
Industry
Biotechnology
CEO
Francois, Cedric
Employees
708
Website
www.apellis.comIPO Date
2017-11-09
Headquarters
100 Fifth Avenue, Waltham, Massachusetts, 02451, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved